The bottom line No arrows from existing clinical evidence point to starting a GLP-1 drug with the intention of microdosing it
Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment
Effect of cereal test breakfasts differing in glycemic index and content of indigestible carbohydrates on daylong glucose tolerance in healthy subjects
Novo Nordisk reported the results from the STEP 1 extension trial on the impact of treatment withdrawal, which found that one year after withdrawal of once-weekly subcutaneous semaglutide 2.4 mg and lifestyle intervention, participants regained two-thirds of their prior weight loss
Retatrutide creates the caloric conditions for fat loss
Navigating the Limitations and Downsides of GLP-1 Medications Font size: Larger Smaller Hits: 5233 0 Comments In the past few years, GLP-1 receptor agonists (GLP-1 RAs) have emerged as a promising class of medications for managing type 2 diabetes
